Zenas BioPharma Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 39.18, 63.25, 130.23, 308.52, 509.91 ], "ebit_estimate": [ -274.33, -317.55, -299.74, -197.75, -56.12 ], "ebitda_estimate": [ -275.94, -296.46, -335.1, null, null ], "net_income_estimate": [ -284.95, -292.73, -305.62, -198.26, -53.95 ], "per_share_eps_estimate": [ -4.83, -4.43, -3.79, -2.62, -0.73 ], "eps_nri_estimate": [ -4.9, -4.53, -4.15, -2.62, -0.73 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 2.6, 2.1, 0.92, null, null ], "pretax_income_estimate": [ -284.95, -324.67, -306.51, -203.71, -62.12 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -123.94, -156.61, -291.84, null, null ], "gross_margin_estimate": [ null, 91.5, 86.5, 87, null ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": 19.83, "long_term_revenue_growth_rate_mean": "126.57", "future_per_share_eps_estimate_growth": 22.03, "future_eps_nri_estimate_growth": 19.83, "future_revenue_estimate_growth": 126.57, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -38.97, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -28.66, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 18.75, null, 26.58, null, 75, 1.65, 5.35 ], "ebit_estimate": [ -64.29, -79.97, -61.65, null, null, null, null ], "ebitda_estimate": [ -79.57, -81.44, -84.03, null, null, null, null ], "net_income_estimate": [ -67.25, -81.62, -63.58, null, null, null, null ], "per_share_eps_estimate": [ -1.08, -1.38, -0.95, -1.14, 3.01, -1.02, -1 ], "eps_nri_estimate": [ -1.13, -1.31, -0.97, -1.14, 3.01, -1.02, -1 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -67.25, -81.62, -63.58, null, null, null, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -114.16, -143.11, -143.16, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 19.83, "long_term_revenue_growth_rate_mean": "126.57", "future_per_share_eps_estimate_growth": 22.03, "future_eps_nri_estimate_growth": 19.83, "future_revenue_estimate_growth": 126.57, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -38.97, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -28.66, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }